Cullinan Therapeutics (CGEM) Non-Current Assets (2020 - 2026)

Cullinan Therapeutics' Non-Current Assets history runs 7 years deep, the most recent figure standing at $41.6 million for Q1 2026.

• In Q1 2026, Non-Current Assets fell 84.13% year-over-year to $41.6 million; the TTM figure through Mar 2026 stood at $489.5 million (down 8.28% YoY), while the FY2025 annual figure was $61.6 million, down 70.26% from the prior year.
• Non-Current Assets for Q1 2026 stood at $41.6 million, down from $61.6 million in the prior quarter.
• The five-year high for Non-Current Assets was $261.9 million in Q1 2025, with the low at $3.4 million in Q2 2024.
• The 5-year median for Non-Current Assets is $61.2 million (2024), against an average of $86.5 million.
• The sharpest annual moves came in 2024 and 2025: Non-Current Assets tumbled 96.8% in 2024, then soared 7053.0% in 2025.
• Cullinan Therapeutics' Non-Current Assets stood at $86.6 million in 2022, then slumped by 95.39% to $4.0 million in 2023, then surged by 5090.58% to $207.2 million in 2024, then tumbled by 70.26% to $61.6 million in 2025, then plunged by 32.52% to $41.6 million in 2026.
• Business Quant data shows CGEM's Non-Current Assets at $41.6 million in Q1 2026, $61.6 million in Q4 2025, and $141.9 million in Q3 2025.